Literature DB >> 24094817

Modular assembly of dimeric HIV fusion inhibitor peptides with enhanced antiviral potency.

Junpeng Xiao1, Thomas J Tolbert.   

Abstract

The HIV-1 envelope gp120/gp41 glycoprotein complex plays a critical role in virus-host cell membrane fusion and has been a focus for the development of HIV fusion inhibitors. In this Letter, we present the synthesis of dimers of HIV fusion inhibitor peptides C37H6 and CP32M, which target the trimeric gp41 in the pre-hairpin intermediate state to inhibit membrane fusion. Reactive peptide modules were synthesized using native chemical ligation and then assembled into dimers with varying linker lengths using Cu(I)-catalyzed azide-alkyne cycloaddition (CuAAC) 'click' chemistry. Cell-cell fusion inhibition assays demonstrated that dimers with a (PEG)7 linker showed enhanced antiviral potency over the corresponding monomers. Moreover, the bio-orthogonal nature of the CuAAC 'click' reaction provides a practical way to assemble heterodimers of HIV fusion inhibitors. Heterodimers consisting of the T20-sensitive strain inhibitor C37H6 and the T20-resistant strain inhibitor CP32M were produced that may have broader spectrum activities against both T20-sensitive and T20-resistant strains.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  C37H6; CP32M; CuAAC; Dimeric HIV fusion inhibitor; HIV; Native chemical ligation; Peptide

Mesh:

Substances:

Year:  2013        PMID: 24094817      PMCID: PMC3832134          DOI: 10.1016/j.bmcl.2013.09.034

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN: 0960-894X            Impact factor:   2.823


  43 in total

1.  A facile ligation approach to prepare three-helix bundles of HIV fusion-state protein mimetics.

Authors:  James P Tam; Qitao Yu
Journal:  Org Lett       Date:  2002-11-14       Impact factor: 6.005

2.  A stepwise huisgen cycloaddition process: copper(I)-catalyzed regioselective "ligation" of azides and terminal alkynes.

Authors:  Vsevolod V Rostovtsev; Luke G Green; Valery V Fokin; K Barry Sharpless
Journal:  Angew Chem Int Ed Engl       Date:  2002-07-15       Impact factor: 15.336

Review 3.  Resistance to enfuvirtide, the first HIV fusion inhibitor.

Authors:  Michael L Greenberg; Nick Cammack
Journal:  J Antimicrob Chemother       Date:  2004-07-01       Impact factor: 5.790

4.  Synthetic bivalent CD4-mimetic miniproteins show enhanced anti-HIV activity over the monovalent miniprotein.

Authors:  Hengguang Li; Haijing Song; Alonso Heredia; Nhut Le; Robert Redfield; George K Lewis; Lai-Xi Wang
Journal:  Bioconjug Chem       Date:  2004 Jul-Aug       Impact factor: 4.774

5.  Cooperative subunit interactions within the oligomeric envelope glycoprotein of HIV-1: functional complementation of specific defects in gp120 and gp41.

Authors:  K Salzwedel; E A Berger
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-07       Impact factor: 11.205

6.  Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy.

Authors:  Xiping Wei; Julie M Decker; Hongmei Liu; Zee Zhang; Ramin B Arani; J Michael Kilby; Michael S Saag; Xiaoyun Wu; George M Shaw; John C Kappes
Journal:  Antimicrob Agents Chemother       Date:  2002-06       Impact factor: 5.191

7.  Design of a modular tetrameric scaffold for the synthesis of membrane-localized D-peptide inhibitors of HIV-1 entry.

Authors:  J Nicholas Francis; Joseph S Redman; Debra M Eckert; Michael S Kay
Journal:  Bioconjug Chem       Date:  2012-05-17       Impact factor: 4.774

8.  Electron tomography analysis of envelope glycoprotein trimers on HIV and simian immunodeficiency virus virions.

Authors:  Ping Zhu; Elena Chertova; Julian Bess; Jeffrey D Lifson; Larry O Arthur; Jun Liu; Kenneth A Taylor; Kenneth H Roux
Journal:  Proc Natl Acad Sci U S A       Date:  2003-12-10       Impact factor: 11.205

Review 9.  The HIV Env-mediated fusion reaction.

Authors:  Stephen A Gallo; Catherine M Finnegan; Mathias Viard; Yossef Raviv; Antony Dimitrov; Satinder S Rawat; Anu Puri; Stewart Durell; Robert Blumenthal
Journal:  Biochim Biophys Acta       Date:  2003-07-11

Review 10.  Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes.

Authors:  Tom Matthews; Miklos Salgo; Michael Greenberg; Jain Chung; Ralph DeMasi; Dani Bolognesi
Journal:  Nat Rev Drug Discov       Date:  2004-03       Impact factor: 84.694

View more
  1 in total

1.  Membrane-Active Sequences within gp41 Membrane Proximal External Region (MPER) Modulate MPER-Containing Peptidyl Fusion Inhibitor Activity and the Biosynthesis of HIV-1 Structural Proteins.

Authors:  Si Min Zhang; Alenka Jejcic; James P Tam; Anders Vahlne
Journal:  PLoS One       Date:  2015-07-31       Impact factor: 3.240

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.